Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Is It Time to Expand Our Definition of "Clinical Utility"?

Cancer control : journal of the Moffitt Cancer Center - 1 Jan 2000

Sorscher Steven

Abstract excerpt

Currently, genetic tests that predict cancer risk or risk of recurrence in patients who have had their cancer treated with curative intent must have proven "clinical utility" to be recommended by the organizations responsible for publishing the standard-of-care guidelines for cancer care.Based on the current definition of clinical utility, most patients are denied testing for cancer-predisposing genes or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA
Share to Early Detection of Cancer
Share to Germ-Line Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Neoplasm, Residual

Share to Patient Satisfaction

Share to Practice Guidelines as Topic

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 37057688
DOI: 10.1177/10732748231170483
PMCID: PMC10108406

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Is It Time to Expand Our Definition of "Clinical Utility"?PMID 37057688Read ↗

Validation and clinical evaluation of a comprehensive circulating tumor DNA assay for genomic profiling in solid tumorsSemantic proximity Read ↗

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.Semantic proximity Read ↗

Molecular Testing for Diagnostics, Prognostication, and Treatment Stratification in Cancers.Semantic proximity Read ↗

Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance.Semantic proximity Read ↗

Circulating-tumor DNA as an early detection and diagnostic tool.Semantic proximity Read ↗

Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare CancersSemantic proximity Read ↗

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.Semantic proximity Read ↗

Your DNA is not your diagnosis: getting diagnoses right following secondary genomic findings.Semantic proximity Read ↗

Circulating Tumor DNA (ctDNA) and Its Role in Gynecologic Malignancies.Semantic proximity Read ↗

Analytical validation and clinical utilization of K-4CARE<sup>TM</sup>: a comprehensive genomic profiling assay with personalized MRD detectionSemantic proximity Read ↗

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint ReviewSemantic proximity Read ↗

Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.